Stemtech Continues to Demonstrate Remarkable Growth and Innovation in 2023
- None.
- None.
Company Achieves NEW Rank Advancements, Acknowledges Sales Directors, and Sets Course for Future Expansion
NAPLES, FL / ACCESSWIRE / December 4, 2023 / Stemtech (OTCQB:STEK), the pioneer in all-natural, plant-based stem cell nutrition wellness solutions, proudly announces a significant milestone with the attainment of NEW Rank Advancements in the recent months in 2023. In these highest rank advancements, we see Diamond, Crown Diamond and Presidents Club achievements. Stemtech extends sincere appreciation to its dedicated Independent Business Partners (IBPs) for their unwavering commitment, hard work, and outstanding performance.
Stemtech's innovative stemceuticalTM technology, backed by patented breakthroughs, mobilizes stem cells from the bone marrow to the bloodstream, showcasing the company's dedication to scientific progress and cutting-edge innovation.
This notable success is a tribute to the dedication and enthusiasm of Stemtech's IBPs. The company acknowledges the crucial role played by its Sales Directors in cultivating an environment of growth and accomplishment.
Special commendations are extended to Maria Felix Rodriguez for achieving the esteemed title of President's Club Director, conducting her business in both the U.S. and Mexico; Olga Lidia de Leon Perez became Crown Diamond; and Ana Nunez reaching Diamond. These accomplishments place them all in an exclusive group, and Stemtech eagerly anticipates the participation of more high-achieving IBPs in this distinguished circle.
"As we witness the rapid advancement of our IBPs through the ranks, Stemtech not only celebrates individual successes but also the collective strength of our global team. The exceptional in the last quarter as well as October and November, reflects our commitment to providing a thriving business opportunity," stated John W. Meyer, President and COO of Stemtech.
The company expresses gratitude to its Sales Directors for their exceptional leadership and guidance, contributing to the remarkable achievements of the entire Stemtech community.
Continuing on this trajectory of success, Stemtech eagerly anticipates the completion of re-entering the Colombian market and expanding its product lines in Ecuador in the early first quarter of 2024. Stemtech is on track to achieve cash flow positivity within the same timeframe, aligning with the strategic objective outlined by CEO Charles S. Arnold. This objective follows a comprehensive company restructure aimed at reducing overhead and positioning Stemtech to handle the anticipated explosive growth in the sector.
Mr. Arnold emphasized, "Our IBPs are the cornerstone of our success, and their swift advancements through the ranks are a testament to the strength of our business model. We are excited about the future, and our plans to re-enter Colombia and expand in Ecuador align with our vision for sustained growth".
Stemtech takes pride in being at the forefront of innovation in the wellness industry, offering not only groundbreaking products but also a rewarding business opportunity. The company remains steadfast in its commitment to providing a platform for individuals worldwide to achieve their health and financial goals.
ABOUT STEMTECH
Stemtech Corporation, a leading stemceuticalTM company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc., which was established in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, Stemtech underwent an extensive executive reorganization, and continued operations under new leadership as Stemtech Corporation. In August 2021, Stemtech became a publicly traded company (OTCQB: STEK) and has expanded business opportunities for its Independent Business Partners, who may earn incomes by sharing Stemtech products. January 2022 saw the introduction of new marketing efforts. In September 2022, the new Stemtech AdvanceOffice mobile app based on the VERB Technology platform was successfully launched as a powerful communication - recruiting tool for our Field On November 1, 2022, Stemtech introduced the new travel/sample size OraStem® Toothpaste. On December 6, Stemtech announced the promotion of Alejandro Carrillo to the role of Vice President Global Sales from his current role as Managing Director Latin Markets. Stemtech introduced the new CellectOneTM Rapid Renew Stem Cell Peptide Night Cream at their December 2022 International Leadership Event in Cancun, Mexico. January 10, 2023 Stemtech appoints Margie and Mike Mares to Field Advisory Board. Stemtech has Ranked Number 11 in Momentum out of 700+ top Global MLM companies by Business For Home independent MLM publication, January 23, 2023. Stemtech conducted Field Leadership Business Academies in Aguas Calientes, Mexico May 25 - 27, and in Las Vegas, NV on June 1 - 3.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on December 1, 2023. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
Investor Relations:
Gabriel Rodriguez
Email: erelationsgroup@gmail.com
Ph: 623-261-9046
Stemtech
Phone: 954-715-6000 ext 1040
Email: invrel@stemtech.com
www.Stemtech.com
SOURCE: Stemtech Corporation
View source version on accesswire.com:
https://www.accesswire.com/812800/stemtech-continues-to-demonstrate-remarkable-growth-and-innovation-in-2023
FAQ
What is the latest news from Stemtech (OTCQB:STEK)?
What are the rank advancements achieved by Stemtech (OTCQB:STEK)?
How does Stemtech's stemceutical technology work?
What are the future expansion plans of Stemtech (OTCQB:STEK)?
